对血清脂质,肥胖和喘之间的因果关系的新见解:孟德尔的随机化研究
Jialiang Sun1, Lanlan Chen2, Peiliang Zhao1
1Department of Pediatric Pulmonary Medicine, Children's Medical Center, The First Hospital of Jilin University, Changchun, Jilin, China.
概括
较高的身体脂肪百分比和体重指数被确定为喘的独立因果风险因素. 这项门德尔随机化研究强调了肥胖和喘发展之间的关键遗传联系.
科学领域:
- 遗传学 是一个遗传学.
- 流行病学 流行病学
- 公共卫生 公共卫生
背景情况:
- 喘是一种复杂的呼吸系统疾病,具有多因素的病因.
- 确定因果风险因素对于有效的预防和治疗策略至关重要.
研究的目的:
- 研究肥胖 (体重指数,体脂百分比) 和血清脂质与喘风险之间的因果关系.
- 使用孟德尔的随机化方法来进行可靠的因果推理.
主要方法:
- 采用了使用全基因组关联研究数据的门德尔随机化 (MR).
- 利用了来自英国生物银行和FinnGen联盟的喘总结级数据.
- 进行了单变量,多变量MR和元分析以评估因果关系.
主要成果:
- 增加的体重指数 (BMI) 和体脂百分比 (BF%) 与更高的喘几率有显著的关联.
- 多变量MR证实BMI和BF%是喘的独立风险因素.
- 高密度脂蛋白胆固醇显示了与喘风险增加的潜在关联.
结论:
- 基因预测较高的BMI和BF%因果上会增加喘风险.
- 肥胖,特别是较高的BMI和BF%,被确定为喘的独立风险因素.
- 这些发现支持针对肥胖的有针对性的干预措施,以减轻喘患病率.
更多相关视频
相关概念视频
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
Obesity
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Asthma-I: Introduction
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
Asthma-II: Pathophysiology and Classification
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Asthma I: Introduction
Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...


